Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 55, Issue 4, 2014, Pages 920-928

  Houldsworth, Jane ^a   Guttapalli, Asha ^a   Thodima, Venkata ^a   Yan, Xiao Jie ^b   Mendiratta, Geetu ^a   Zielonka, Tania ^c   Nanjangud, Gouri ^d   Chen, Weiyi ^a   Patil, Sujata ^d   Mato, Anthony ^c   Brown, Jennifer R ^e   Rai, Kanti ^b   Chiorazzi, Nicholas ^b   Chaganti, R S K ^d  

^a CANCER GENETICS INC   (United States)

^b Feinstein Institute of Medical Research   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Lymphoid leukemia; Molecular genetics; Prognostication

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN HEAVY CHAIN; TUMOR MARKER;

ADVERSE OUTCOME; ARTICLE; CANCER GROWTH; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 18P; CHROMOSOME 18Q; CHROMOSOME 19; CHROMOSOME 1P; CHROMOSOME 2P; CHROMOSOME 3Q; CHROMOSOME 4P; CHROMOSOME 5P; CHROMOSOME 6Q; CHROMOSOME 7P; CHROMOSOME 7Q; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENOME; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NOTCH1 RECEPTOR GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN P53 GENE; RISK ASSESSMENT; SF3B1 GENE; CANCER STAGING; CHROMOSOME 13; CHROMOSOME ABERRATION; FEMALE; GENETICS; GENOMICS; INFORMATION PROCESSING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MORTALITY; MUTATION; PROGNOSIS;

CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 13; COMPARATIVE GENOMIC HYBRIDIZATION; DATASETS AS TOPIC; FEMALE; GENOMICS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MUTATION; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904319260     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.845882     Document Type: Article

References (43)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
2. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847. (Pubitemid 29430399)
3. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854. (Pubitemid 29430400)
4. NCCN. Non-Hodgkin's Lymphomas. NCCN Clinical Practice Guidelines in Oncology 2011;Version 4.2011. Available from: http://www.nccn.org/professionals/ physician-gls/pdf/nhl.pdf
5. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006;24: 4634-4641. (Pubitemid 46630962)
6. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916. (Pubitemid 32064784)
7. Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 mutations in CLL associated with trisomy 12.Blood 2012; 119: 329-331.
8. Grubor V, Krasnitz A, Troge JE, et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood 2009; 113: 1294-1303.
9. Rinaldi A, Mian M, Kwee I, et al. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. Br J Haematol 2011; 154: 590-599.
10. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389-1401.
11. PuenteXS, Pinyol M, QuesadaV, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
12. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.Blood 2012;119:521-529.
13. Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011;29:2223-2229.
14. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473-4479.
15. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011;118: 6904-6908.
16. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365: 2497-2506.
17. Rossi D, Deaglio S, Dominguez-Sola D, et al. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood 2011; 118: 4930-4934.
18. Brown JR, Hanna M, Tesar B, et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 2012; 18: 3791-3802.
19. Gunn SR, Mohammed MS, Gorre ME, et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn 2008; 10: 442-451.
20. Ouillette P, Collins R, Shakhan S, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 2011; 118: 3051-3061.
21. Pfeifer D, Pantic M, Skatulla I, et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 2007; 109: 1202-1210. (Pubitemid 46220669)
22. Ouillette P, Collins R, Shakhan S, et al. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin Cancer Res 2011;17:6778-6790.
23. Ouillette P, Erba H, Kujawski L, et al. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 2008;68:1012-1021. (Pubitemid 351272218)
24. Dal Bo M, Rossi FM, Rossi D, et al. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes Cancer 2011; 50: 633-643.
25. Mian M, Rinaldi A, Mensah AA, et al. Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. Hematol Oncol 2012; 30: 46-49.
26. Mosca L, Fabris S, Lionetti M, et al. Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion. Clin Cancer Res 2010;16: 5641-5653.
27. Lia M, Carette A, Tang H, et al. Functional dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines. Blood 2012; 119: 2981-2990.
28. Swerdlow S, Campo, E, Harris, NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
29. Gunnarsson R, Mansouri L, Isaksson A, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 2011; 96: 1161-1169.
30. Kujawski L, Ouillette P, Erba H, et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 2008; 112: 1993-2003.
31. Schultz RA, Delioukina M, Gaal K, et al. Evaluation of chronic lymphocytic leukemia by BAC-based microarray analysis. Mol Cytogenet 2011; 4: 4.
32. Fabris S, Mosca L, Cutrona G, et al. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. Am J Hematol 2013; 88: 24-31.
33. Woyach JA, Heerema NA, Zhao J, et al. Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease. Br J Haematol 2010; 148: 754-759.
34. Rudenko HC, Else M, Dearden C, et al. Characterising the TP53- deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation.Leuk Lymphoma 2008; 49: 1879-1886.
35. Kay NE, Eckel-Passow JE, Braggio E, et al. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet 2010;203:161-168.
36. Stankovic T, Skowronska A. The role ofATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. Leuk Lymphoma 2013 Sep 12. [Epub ahead of print]
37. Forconi F, Rinaldi A, Kwee I, et al. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. Br J Haematol 2008;143: 532-536.
38. Cuneo A, Rigolin GM, Bigoni R, et al. Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. Leukemia 2004; 18: 476-483. (Pubitemid 38425861)
39. Parker H, Rose-Zerilli MJ, Parker A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia 2011; 25: 489-497.
40. Rossi EA, Rossi DL, Cardillo TM, et al. Preclinical studies on targeted delivery of multiple IFNalpha2b to HLA-DR in diverse hematologic cancers. Blood 2011; 118: 1877-1884.
41. Brown JR, Hanna M, Tesar B, et al. Germline copy number variation associated with Mendelian inheritance of CLL in two families. Leukemia 2012; 26: 1710-1713.
42. Van Dyke DL, Shanafelt TD, Call TG, et al. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol 2010; 148: 544-550.
43. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012; 119: 2854-2862.